{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:10:13Z","timestamp":1759104613921,"version":"3.44.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ijcard.2020.10.070","type":"journal-article","created":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T23:48:45Z","timestamp":1604274525000},"page":"98-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy and safety of direct oral anticoagulants in patients undergoing elective electrical cardioversion: A real-world patient population"],"prefix":"10.1016","volume":"326","author":[{"given":"John","family":"de Heide","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit E.","family":"Bhagwandien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amira","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaleesa","family":"Gros-Bisdom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen C.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sip A.","family":"Wijchers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Zijlstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamas","family":"Szili-Torok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattie J.","family":"Lenzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sing-Chien","family":"Yap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.ijcard.2020.10.070_bb0005","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J."},{"issue":"38","key":"10.1016\/j.ijcard.2020.10.070_bb0010","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.ijcard.2020.10.070_bb0015","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2013.09.062","article-title":"Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE trial (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation)","volume":"63","author":"Flaker","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.ijcard.2020.10.070_bb0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.110.977546","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion","volume":"123","author":"Nagarakanti","year":"2011","journal-title":"Circulation."},{"issue":"19","key":"10.1016\/j.ijcard.2020.10.070_bb0025","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2013.02.025","article-title":"Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial","volume":"61","author":"Piccini","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2020.10.070_bb0030","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/clc.22537","article-title":"Cardioversion of atrial fibrillation in ENGAGE AF-TIMI 48","volume":"39","author":"Plitt","year":"2016","journal-title":"Clin. Cardiol."},{"issue":"47","key":"10.1016\/j.ijcard.2020.10.070_bb0035","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehu367","article-title":"Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation","volume":"35","author":"Cappato","year":"2014","journal-title":"Eur. Heart J."},{"issue":"32","key":"10.1016\/j.ijcard.2020.10.070_bb0040","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1093\/eurheartj\/ehy148","article-title":"Apixaban compared to heparin\/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial","volume":"39","author":"Ezekowitz","year":"2018","journal-title":"Eur. Heart J."},{"issue":"10055","key":"10.1016\/j.ijcard.2020.10.070_bb0045","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","article-title":"Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial","volume":"388","author":"Goette","year":"2016","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/j.ijcard.2020.10.070_bb0050","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/europace\/eux116","article-title":"Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion","volume":"20","author":"Itainen","year":"2018","journal-title":"Europace."},{"issue":"7","key":"10.1016\/j.ijcard.2020.10.070_bb0055","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/europace\/eux188","article-title":"Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin","volume":"20","author":"Frederiksen","year":"2018","journal-title":"Europace."},{"issue":"7","key":"10.1016\/j.ijcard.2020.10.070_bb0060","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.hlc.2017.06.726","article-title":"Novel Oral anticoagulants in direct current Cardioversion for atrial fibrillation","volume":"27","author":"Femia","year":"2018","journal-title":"Heart Lung Circ."},{"issue":"10","key":"10.1016\/j.ijcard.2020.10.070_bb0065","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/europace\/euv123","article-title":"Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism?","volume":"17","author":"Johansson","year":"2015","journal-title":"Europace."},{"issue":"7","key":"10.1016\/j.ijcard.2020.10.070_bb0070","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.amjcard.2018.06.022","article-title":"Outcomes with novel Oral anticoagulants in obese patients who underwent electrical Cardioversion for atrial Tachyarrhythmias","volume":"122","author":"Kaplan","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.10.070_bb0075","doi-asserted-by":"crossref","DOI":"10.1111\/anec.12766","article-title":"Real-life experience with non-vitamin K antagonist oral anticoagulants versus warfarin in patients undergoing elective cardioversion of atrial fibrillation","volume":"25","author":"Itainen-Stromberg","year":"2020","journal-title":"Ann. Noninvasive Electrocardiol."},{"issue":"1","key":"10.1016\/j.ijcard.2020.10.070_bb0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.joa.2016.04.003","article-title":"Non-vitamin K antagonist oral anticoagulants versus warfarin for cardioversion of atrial fibrillation in clinical practice: a single-center experience","volume":"33","author":"Shibata","year":"2017","journal-title":"J. Arrhythm."},{"issue":"6","key":"10.1016\/j.ijcard.2020.10.070_bb0085","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/pace.12618","article-title":"Novel Oral anticoagulants for DC Cardioversion procedures: utilization and clinical outcomes compared with warfarin","volume":"38","author":"Coleman","year":"2015","journal-title":"Pacing Clin. Electrophysiol."},{"issue":"12","key":"10.1016\/j.ijcard.2020.10.070_bb0090","first-page":"1541","article-title":"Comparison of outcomes after cardioversion or atrial fibrillation ablation in patients with differing periprocedural anticoagulation regimens","volume":"30","author":"Kochhauser","year":"2014","journal-title":"Can. J. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcard.2020.10.070_bb0095","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Subcommittee on control of anticoagulation of the S, standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.ijcard.2020.10.070_bb0100","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","article-title":"Interobserver agreement for the assessment of handicap in stroke patients","volume":"19","author":"van Swieten","year":"1988","journal-title":"Stroke."},{"issue":"1","key":"10.1016\/j.ijcard.2020.10.070_bb0105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/europace\/euu189","article-title":"Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy","volume":"17","author":"Hansen","year":"2015","journal-title":"Europace."},{"issue":"2","key":"10.1016\/j.ijcard.2020.10.070_bb0110","doi-asserted-by":"crossref","first-page":"50","DOI":"10.15420\/aer.2017:3:2","article-title":"Practical implementation of anticoagulation strategy for patients undergoing Cardioversion of atrial fibrillation","volume":"6","author":"Goette","year":"2017","journal-title":"Arrhythmia Electrophysiol. Rev."},{"issue":"10","key":"10.1016\/j.ijcard.2020.10.070_bb0115","first-page":"426","article-title":"Trends in direct oral anticoagulant (DOAC) use: health benefits and patient preference","volume":"76","author":"de Jong","year":"2018","journal-title":"Neth. J. Med."},{"issue":"10","key":"10.1016\/j.ijcard.2020.10.070_bb0120","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s12471-016-0874-y","article-title":"The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF)\u202f: Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands","volume":"24","author":"Ten Cate","year":"2016","journal-title":"Neth. Hear. J."},{"issue":"2","key":"10.1016\/j.ijcard.2020.10.070_bb0125","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/europace\/euv294","article-title":"Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial","volume":"18","author":"Hohnloser","year":"2016","journal-title":"Europace."},{"issue":"3","key":"10.1016\/j.ijcard.2020.10.070_bb0130","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1060028017737095","article-title":"Direct Oral anticoagulants in Cardioversion: a review of current evidence","volume":"52","author":"Gibson","year":"2018","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.ijcard.2020.10.070_bb0135","doi-asserted-by":"crossref","first-page":"805","DOI":"10.4081\/monaldi.2017.805","article-title":"Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials","volume":"87","author":"Di Fusco","year":"2017","journal-title":"Monaldi Arch. Chest Dis."},{"issue":"1","key":"10.1016\/j.ijcard.2020.10.070_bb0140","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1038\/s41598-019-39925-5","article-title":"Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation - a meta-analysis of more than 17000 patients","volume":"9","author":"Mincu","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijcard.2020.10.070_bb0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2017.07.048","article-title":"NOACs and atrial fibrillation: incidence and predictors of left atrial thrombus in the real world","volume":"249","author":"Bertaglia","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.10.070_bb0150","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijcard.2015.02.075","article-title":"Transesophageal echocardiograpy in patients with persistent atrial fibrillation undergoing electrical cardioversion on new oral anticoagulants: a multi center registry","volume":"184","author":"Stabile","year":"2015","journal-title":"Int. J. Cardiol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527320340614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527320340614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:51:19Z","timestamp":1759092679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527320340614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":30,"alternative-id":["S0167527320340614"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.10.070","relation":{},"ISSN":["0167-5273"],"issn-type":[{"type":"print","value":"0167-5273"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of direct oral anticoagulants in patients undergoing elective electrical cardioversion: A real-world patient population","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.10.070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}